Evidence map›Paper›PMID 42553432›Full record

ArticleCureus2026

Severe Cardiovascular Collapse Associated With Remimazolam-Based Anesthetic Induction: A Case Series of Three Elderly Patients.

Donghyo Kim, Eunju Kim

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Donghyo KimAnesthesiology, Daegu Fatima Hospital, Daegu, KOR.
Eunju KimAnesthesiology, Daegu Fatima Hospital, Daegu, KOR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Remimazolam is an ultra-short-acting benzodiazepine that is increasingly used for the induction and maintenance of general anesthesia owing to its favorable hemodynamic profile. However, severe perioperative hypersensitivity reactions associated with its use have been reported. We report three cases of elderly patients who experienced severe cardiovascular collapse immediately after anesthetic induction with remimazolam. Additionally, an institutional review conducted over an 18-month study period identified six suspected perioperative hypersensitivity reactions. All six patients were elderly and developed sudden cardiovascular or respiratory instability shortly after induction of anesthesia with remimazolam and rocuronium. Of these, three patients experienced severe cardiovascular collapse requiring epinephrine administration or cardiopulmonary resuscitation, and two progressed to cardiac arrest. Cutaneous manifestations were absent or minimal in several cases, whereas a marked reduction in end-tidal CO₂ and refractory hypotension were the predominant clinical features. In selected cases, elevated histamine or tryptase levels provided evidence of mast-cell activation. Although rocuronium remains an important alternative causative agent, the temporal relationship with remimazolam administration, the recurrence pattern within the institution, and the uneventful subsequent anesthesia with alternative regimens in some patients suggest that remimazolam or its formulation components should be considered among the potential triggers. These cases highlight the need for early recognition of perioperative hypersensitivity when abrupt cardiovascular collapse and a sudden decrease in end-tidal CO₂ occur during induction, even in the absence of skin findings.

Indexed as

anaphylaxisanesthesia inductioncardiac arrestcardiovascular collapseelderly patientsend-tidal carbon dioxideperioperative hypersensitivityremimazolam

Identifiers

PMID42553432
PMCPMC13435184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.